about
Effects of oral lycopene supplementation on vascular function in patients with cardiovascular disease and healthy volunteers: a randomised controlled trialThe role of epoxyeicosatrienoic acids in the cardiovascular systemSimvastatin prevents inflammation-induced aortic stiffening and endothelial dysfunction.Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonistTetrahydrobiopterin Supplementation Improves Endothelial Function But Does Not Alter Aortic Stiffness in Patients With Rheumatoid Arthritis.Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers.The Role of the Autonomic Nervous System in the Regulation of Aortic Stiffness.Therapeutic potential of p38 MAP kinase inhibition in the management of cardiovascular disease.Quantification of Lung PET Images: Challenges and Opportunities.The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans.Evaluation of the Vicorder, a novel cuff-based device for the noninvasive estimation of central blood pressure.Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction.Aldehyde dehydrogenase 2 plays a role in the bioactivation of nitroglycerin in humans.The accuracy of central SBP determined from the second systolic peak of the peripheral pressure waveform.Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia.Anti-IL-7 receptor α monoclonal antibody (GSK2618960) in healthy subjects - a randomized, double-blind, placebo-controlled studyPrimary prevention of CVD: treating hypertensionAnti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritisRisk assessment for hospital admission in patients with COPD; a multi-centre UK prospective observational studyClinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure SubjectsNon-invasive measurements of arterial function: What? When? Why should we use them?
P50
Q21089697-6B1DD364-7FEE-4A49-A3ED-E65DC1A06E96Q28256560-C39105A9-0CAC-4C34-A7D2-78F87D4463F1Q34457410-A924B148-FAFA-42DA-B993-79B82571C151Q35161744-FB033B84-DC35-45DB-8821-D18EF2F797F1Q36714071-A54365F4-2123-4954-9DA9-EE2FD2038DCDQ36988007-65D1DD9B-A777-4561-9529-E9BCD80B326EQ37327344-55BD3D5A-BF0D-4D8B-A060-F4F7814FEC51Q38185979-DC4FADB9-028E-4419-ADA7-4C1B6741A380Q38771134-A05B8198-A0EE-4DA9-8081-D60F4221066BQ42283626-7555BAC6-C7D7-4C73-AAEB-A500C8AD1C53Q44953015-79445889-E31A-4C5F-8604-AF512F87A9C9Q46525801-88685D4E-266D-4D3D-8D41-0E3964CC39DDQ46624700-68BC2D81-43FF-45AA-9D76-C6CF328541EDQ53059741-A6A9EC0C-FE0C-4C3B-BE41-6DD66263146FQ53142391-B1EC0C8A-E9A6-47D4-AB3A-1FD2F4737703Q54617917-CA7C0829-48BC-494F-80A7-9AFCC1DE9AF8Q61453292-5A269000-8ABF-409E-91CC-F7891E79AA77Q84512081-1B785B33-B60B-4128-8A24-DE05BFA4227AQ85264043-3D23B4D7-9038-4134-BDB7-ADCF436B8D34Q89629336-FF847A61-3728-49FF-AB81-9354D8E14E0FQ91022137-D0C34540-1B94-4146-B223-0BF716524771Q92077182-197DF3A5-40D2-4B8E-A780-4B7FB3AED888
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Joseph Cheriyan
@ast
Joseph Cheriyan
@en
Joseph Cheriyan
@es
Joseph Cheriyan
@nl
Joseph Cheriyan
@sl
type
label
Joseph Cheriyan
@ast
Joseph Cheriyan
@en
Joseph Cheriyan
@es
Joseph Cheriyan
@nl
Joseph Cheriyan
@sl
prefLabel
Joseph Cheriyan
@ast
Joseph Cheriyan
@en
Joseph Cheriyan
@es
Joseph Cheriyan
@nl
Joseph Cheriyan
@sl
P1053
B-2596-2009
P106
P1153
56594723500
P21
P2798
P31
P3829
P496
0000-0001-6921-1592